glp-1 conversion PDF] Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance 6/n: The GLP-1 Goldrush has

The approval granted on October 7, 2025, and marks the first new therapy for IPF in more than ten years

While studies sponsored by leading pharmaceutical companies suggest a much higher likelihood of weight regain, those studies are not reflective of the average person with obesity

To qualify, beneficiaries must be enrolled in an eligible Part D plan and have a BMI of 27 or higher with at least one qualifying comorbidity such as heart disease or prediabetes, or a BMI of 35 or higher regardless of comorbidities

Sulfur burps alone are not typically a reason to stop treatment

Patients may or may not obtain follow-up and/or referrals to RDs

The typical ingredient list: berberine extract, cinnamon extract, pomegranate extract, green tea extract (EGCG), B vitamins, L-glutamine, and chromium